A Case Study Series to Evaluate the Safety and Efficacy of a Novel Keratolytic in Patients Diagnosed with Plaque Psoriasis

Page s2

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from an Ongoing Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

Page s3

Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: DLQI and WPAI Patient-Reported Outcomes from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Page s4

Clinical Responses in Patients with Moderate-to-Severe Plaque Psoriasis Following Withdrawal and Re-Treatment with Risankizumab or Switching from Ustekinumab to Risankizumab

Page s5

Cost Per Responder Analysis of Guselkumab versus Adalimumab using Efficacy Results fromm a Head-to-Head Clinical Trial in Patients with Moderate to Severe Plaque Psoriasis

Page s6

Defining and Treating Moderate Plaque Psoriasis in a Real-World Clinical Setting: A Dermatologist Survey and Prospective 6-Month Chart Review of Patients Treated with Apremilast

Page s7

DFD-01, a Betamethasone Dipropionate 0.05% Spray, Improved Quality of Life and Treatment Satisfaction in Subjects with Moderate Psoriasis

Page s8

DFD-01, a VCA midpotent beteamethasone dipropionate 0.05% emollient-like spray formulation, demonstrates earlier onset of action compared with a super potent topical steroid for the treatment of moderate psoriasis

Page s9

Distribution of Improvements in Psoriasis Area and Severity Index from the Phase 2 Trial of Risankizumab in Moderate-to-Severe Plaque Psoriasis

Page s10

Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase IV Study)

Page s11

Efficacy, Health-Related Outcomes, and Safety of Ixekizumamb for up to Five Years of Open-Label Treatment in a Phase 2 Study in Chronic Plaque Psoriasis

Page s12

Efficacy of Apremilast on Quality-of-Life Measures in Patients with Moderate Plaque Psoriasis (UNVEIL Phase IV Study)

Page s13

Evaluation of the PGAxBSA Composite Tool in Patients with Moderate-to-Severe Plaque Psoriasis

Page s14

First "Real-World" Insights on Apremilast Treatment for Patients with Plaque Psoriasis from the LAPIS-PSO Study: An Interim Analysis

Page s15

Group Concept Mapping to Understand the Patient Perspective and Burden of Psoriasis

Page s16

Improvements in Lesional Pain and Itch Symptoms with Brodalumab in Psoriasis Studies

Page s17

Incidence of Inflammatory Bowel Disease Events in Adalimumab Clinical Trials Across Indications

Page s18

Innovation in Topical Therapy for Psoriasis with Corticostereoid and Vitamin D Analogue Commbination

Page s19

Keratolytic Activity of a Novel Dimethicone Formulation (PB/LO-112) Compared to 10% Salicylic Acid Oil in Patients with Psoriasis Capitis

Page s20

Lack of Placental Transfer of Certolizumab Pegol During Pregnancy: Results from CRIB, a Prospective, Postmarketing, Multicenter, Pharmacokinetic Study

Page s21

Long-Term Safety and Effectiveness of Adalimumab for Moderat-to-Severe Psoriasis: Results from the Eight-Year Interim Analysis of the ESPIRIT Registry

Page s22

Maintenance of Response with Certolizumab Pegol for the Treatment of Chronic Plaque Psoriasis: 48-Week Results from Two Ongoing Phase 3, Multicenter, Randomized, Placebo-Controlled Studies (CIMPASI-1 and CIMPASI-2)

Page s23

Maintenance of Response with Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT)

Page s24

Neuropsychiatric Adverse Events in Brodalumab Psoriasis Studies

Page s25

Patient Preference for Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam or Topical Suspension vs. Latest Topical Treatment in the PSO-INSIGHTFUL Study

Page s26

Permeation Analysis of Novel Steroid Vehicles to Deliver and Retain Steroid in Skin Layers Associated with Psoriasis

Page s27

Radiographic Progression of Structural Joint Damage in Patients with Active Psoriatic Arthritis Treated with Ixekizumab over 52 Weeks

Page s28

A Randomized, Double-Blind, Multicenter Study to Compare the Efficacy, Safety, and Immunogenicity of a Proposed Adalimumab Biosimilar (GP2017) with Originator Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis

Page s29

Results of Subject's Assessment of Behavior and Attitudes (SABA) Survey Toward Psoriasis and Treatments in the PSO-INSIGHTFUL Study

Page s30

A Retrospective Cohort Study of Real-World Experience with Apremilast in Patients with Plaque Psoriasis

Page s31

Safety and Efficacy of Apremilast Through 104 Weeks in Patients swith Moderate-to-Severe Psoriasis Who Continued on Apremilast or Switched from Etanercept Treatment in the LIBERATE Study

Page s32

XP-23829, a Novel Fumaric Acid Ester, is Efficacious in Reducing Psoriatic Lesions: Results from a Phase 2 Randomized Controlled Study

Page s33

Can the Skin Microbiota of Patients Suffering from Atopic Dermatitis be Modified after Balneotherapy?

Page s34

Comparison of an Anhydrous OTC Balm Containing 15% Zinc Oxide, 2% Colloidal Oatmeal, and 1% Allantoin Versus 1% Hydrocortisone Cream in Subjects with Mild-to-Moderate Dermatitis

Page s35

Direct and Indirect Effects of Crisaborole Ointment on Quality of Life in Patients with Atopic Dermatitis: A Mediation Analysis

Page s36

Dupilumab with Concomitant Topical Corticosteroids in Atopic Dermatitis Patients who are Inadequately Controlled with or Medically Inadvisable for Cyclosporine A: a Phase 3 Clinical Trial (LIBERTY AD CAFE)

Page s37

Dupilumab in Moderate-to-Severe Atopic Dermatitis: Pooled Efficacy Results from Two Identically Designed Randomized Phase 3 Trials (SOLO 1 & 2)

Page s38

The Effect of Crisaborole Ointment, 2%, on Pruritus in Patients with Atopic Dermatitis: An Extended Analysis

Page s39

An Investigator Blinded Randomized Study Evaluating HOCl in the Treatment of Atopic Dermatitis-Associated Pruritus

Page s40

A Moisturizing Spray Ointment to Help Alleviate Dry Skin Symptoms Associated with Atopic Eczema, Psoriasis, and Xerosis

Page s41

Observational Study on Patients with Atopic Dermatitis

Page s42

Topical Treatment Utilization for Patients with Atopic Dermatitis in the United States and Budget Impact Analysis of Crisaborole Ointment, 2%

Page s43

Using a Specific Cleanser for Patients with Mild Atopic Dermatitis: Relationship Between Cinical Efficacy and Skin Microbiota Modification

Page s44

Validation of the Severity of Pruritus Scale for the Assessment of Pruritus in Atopic Dermatitis

Page s45

Adalimumab Efficacy in Hidradenitis Suppurativa Patients is Sustained at Least Three Years with Weekly Dosing: Results from a Phase 3 Open-Label Extension Study (PIONEER)

Page s128

Continuous Weekly Adalimumab is the Optimal Long-Term Strategy for Patients with Moderate-to-Severe Hidradenitis Suppurativa: Results from the PIONEER Open Label Extension Trial

Page s129

Impact of Baseline Smoking Status and Body Mass Index in Patients with Hidradenitis Suppurativa Treated with Adalimumab or Placebo in Phase 2 or 3 Studies

Page s130

DFD-03 (0.1% Tazarotene), Twice-daily, Short-Contact Lotion Formulation, Showed Similar Pharmacokinetic Exposure to the Marketed Cream Product with Once-Daily Overnight Application

Page s46

Effect of Air Pollution on Sebum Rate and Acne: How to Manage Acneic Skin in a Polluted Environment

Page s47

Efficacy and Saftey of Adapalene 0.3%/Benzoyl Peroxide 2.5% Gel Plus Doxycycline in Subjects with Severe Inflammatory Acne (Non-Nodulocystic) that are Candidates for Oral Isotretinoin

Page s48

The Efficacy and Safety of FMX101, Minocycline Foam 4%, for the Treatment of Acne Vulgaris: A Pooled Analysis of Phase 2 and Phase 3 Studies

Page s49

Efficacy and Tolerability of Tazarotene Foam 0.1% Across Age, Gender, and Race: An Integrated Review of Two Phase III Trials

Page s50

Observational Study on Patients with Acne and at Risk of Post-Inflammatory Hyperpigmented Lesions

Page s51

Pharmacokinetic Evaluation of Once-Daily Topical 4% Minocycline Foam in Adult and Pediatric Subjects with Moderate-to-Severe Acne in Two Phase 1 Studies

Page s52

Rapid Improvement with BPX-01 Minocycline Topical Gel in the Treatment of Moderate-to-Severe Inflammatory Acne Vulgaris: a Randomized, Double-Blind, Vehicle-Controlled Study

Page s53

Skin Microbiome and Acne Vulgaris: Staphylococcus, a New Actor in Acne

Page s54

Topical Green Tea Polyphenols and Caffeine as a Treatment for Acne Vulgaris

Page s55

The Use of Lipohydroxy Acid in Skin Care and Acne Treatment

Page s56

Visualization of Cutaneous Distribution of Minocycline of a Topical Gel in Human Facial Skin with Two-Photon Excited Fluorescence Lifetime Imaging Microscopy (FLIM) and Phasor Analysis

Page s57

Efficacy and Tolerance of a New Non-Steroidal Prescription Cream in the Treatment of Mild Facial Seborrheic Dermatitis

Page s134

Bensal HP (BHP-410), a Novel Antimicrobial Agent with Activity Against MRSA, VRE, Gram-negative MDROs, Yeasts, and Dermatophytic Fungi

Page s135

The Effect of Econazole Nitrate Topical Foam, 1% on Signs and Symptoms (Pruritis) of Interdigital Tinea Pedis

Page s136

Ex-vivo Determination of Antifungal Activity of a New Prescription Non-Steroidal Facial Cream Against Malassezia furfur in Human Skin Explants

Page s137

An Open-Label Exploratory Study Evaluating the Efficacy and Safety of Ingenol Mebutate Gel 0.05% for the Treatment of Verruca Vulgaris

Page s138

The Role of Cutaneous Microbiota Harmony in Maintaining a Functional Skin Barrier

Page s139

Clinical Efficacy and Tolerability of a Cosmetic Growth Factor Serum for Overall Facial Photodamage

Page s64

A Comprehensive Analysis of the Safety of a New Range of Injectable Hyaluronic Acid Products for Aesthetic Indications

Page s65

Differential Facial Aesthetic Treatment Considerations for Skin of Color Populations: African American, Asian, and Hispanic

Page s66

DFD-01, a Betamethasone Dipropionate 0.05% Spray Lotion. Reduces Transepidermal Water Loss and Improves Skin Hydration and Elasticity

Page s67

Efficacy and Consumer Perception of a 96% Natural Cream Containing Lime Pearl Extract and Willow Bark Extract when Used by Subjects with Clinically Determined Keratosis Pilaris

Page s68

An Effective yet Gentle Foaming Facial Cleanser Specifically Designed for Redness-Prone Skin

Page s69

Efficacy of IncobotulinumtoxinA for the Treatment of Glabellar Frown Lines in Male Subjects: Post-Hoc Analyses from Randomized. Double-Blind Pivotal Studies

Page s70

Efficacy of an Ointment Body Spray to Improve the Appearance of Dry, Ashy Skin and Alleviate Moderate to Severe Dryness on the Heel

Page s71

Efficacy and Safety of OnabotulinumtoxinA for Treatment of Moderate-to-Severe Forehead Lines

Page s72

Efficacy and Safety of OnabotulinumtoxinA for Moderate-to-Severe Forehead Lines in Subjects with Upper Facial Lines

Page s73

Evaluation of the Efficacy and Tolerability of a Topical Facial Serum in Improving Signs of Aging

Page s74

How to Treat Dryness, Hyperkeratosis, and Cracks of Diabetic Patients' Feet

Page s75

Immediate and Long-Term Efficacy of a Two-Step Topical Hyaluronic Acid Lip Treatment

Page s76

Juvederm Vollure XC is Safe and Effective for Correcting Nasolabial Folds: Results from a Randomized Controlled Study

Page s77

Juvederm Vollure XC is Safe and Effective for Long-Term Correction of Nasolabial Folds: Results from a Multicenter, Randomized, Controlled Study

Page s78

Lip and Perioral Enhancement with HA Dermal Fillers in Individuals with Fitzpatrick Skin Types IV-VI

Page s79

Maximizing Pan-Facial Aesthetic Outcomes; Findings and Recommendations from the HARMONY Study

Page s80

An Observational Study of the Safety and Efficacy of Tissue Stabilized-Guided Subcision to Improve the Appearance of Cellulite

Page s81

OnabotulinumtoxinA for Treatment of Moderate-to-Severe Horizontal Lines and Glabellar Lines from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

Page s82

An Open Label, Prospective, Clinical Study to Evaluatee the Anti-aging Effects and the Safety of a Novel Ccosmetic Facial Day Cream

Page s83

Pan-facial Treatment Positively and Significantly Impacts Social Perception

Page s84

Performance of a Facial Night Moisturizer for Redness-Prone Skin

Page s85

The Psychological Impacts of Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines: Qualitative, Patient-Centered Studies

Page s86

Reduction of Facial Redness with Resveratrol Added to Topical Product Containing Green Tea Polyphenols and Caffeine

Page s87

Simultaneous Treatment of Moderate-to-Severe Horizontal Frontalis Lines, Glabellar Lines, and Lateral Canthal Lines wtih OnabotulinumtoxinA from the Subject's Perspective: Patient-Reported Satisfaction and Impact Outcomes from a Phase 3 Double-Blind Study

Page s88

A Split-Face Design Clinical Trial to Evaluate the Efficacy of a Masque when Used Post-Full Face Fraxel® Laser Treatment

Page s89

Tolerability and Efficacy of a Moisturizing Broad Spectrum Sunscreen Formulated for Redness-Prone Skin

Page s90

Two On-Label Injection Volumes of AbobotulinumtoxinA (ABO) Produce Simlar Safety and Efficacy Results when Used to Treate Moderate to Sever Glabellar Lines

Page s91

VYC-17.5L is Effective for the Treatment of Static and Dynamic Radial Cheek Lines: Results from the BEAM Study

Page s92

31-Gene Expression Profile Assessing Metastatic Risk in Melanoma Patients: Issues Impacting Patient Selection

Page s105

Clinical Reliability and Reproducibility of a Prognostic 31-Gene Expression Profile Test for Cutaneous Melanoma, and Association of the Test with Standard Clinicopathologic Factors

Page s106

Clinical Impact of a 31-Gene Expression Profile Test on Physician Recommendations for Management of Melanoma Patients in a Prospectively Tested Cohort

Page s107

Comparing Electrical Impedance Spectroscopy to Traditional Clinical Adjunctive Tools in the Detection of Melanoma

Page s108

Health Econommic Implications of a Non-Invasive Gene Expression Test for Primary Cutaneous Melanoma

Page s109

Interim Analysis of Survival Outcomes in a Prospective Multicenter Cohort Evaluating a Prognostic 31-Gene Expression Profile (GEP) Test for Melanoma

Page s110

Adalimumab for Nail Psoriasis: Efficacy and Safety from the Open-Label Extension of a Phase-3, Randomized, Placebo-Controlled Trial

Page s97

Efinaconazole 10% and Tavaborole 5% Penetrate Across Poly-ureaurethane 16%: Results of In Vitro Release Testing and Clinical Implications of Onychodystrophy in Onychomycosis

Page s98

Improvement of Nail Psoriasis with Brodalumab in Phase 3 Trials

Page s99

Clinical Efficacy and Tolerability of a Topical HQ-Free Serum on Females with self-Reported Pregnancy-Induced Facial Melasma

Page s100

Combining In-Office Chemical Peel Procedures with Topical Therapy of a Comprehensive Pigmentation Control Product for Multi-Ethnic Subjects with Moderate-to-Severe Facial Hyperpigmentation

Page s101

Ozenoxacin, a Novel, Topical Antibacterial Agent for Treatment of Adult and Pediatric Patients with Impetigo: Phase III Clinical Trials Pooled Analysis Results

Page s102

A Randomized Vehicle-Controlled Trial to Assess the Efficacy, Safety, and Tolerability of Ozenoxacin 1% Cream in 412 Patients 2 Months and Older with Impetigo

Page s103

A Randomized Vehicle-Controlled Trial to Assess the Efficacy, Safety, and Tolerability of Ozenoxacin 1% Cream in 465 Patients 2 Years and Older with Impetigo

Page s104

Burden of Axillary Hyperhidrosis Using a Patient-Reported Outcome Measure to Assess Impact on Activities and Bothersomeness

Page s93

Confirmatory Psychometric Evaluation of the Axillary Sweating Daily Diary: A Vaildated Patient-Reported Outcome Measure to Assess Axillary Hyperhidrosis Sweating Severity

Page s94

Open-Label Study (ARIDO) Evaluating Long-Term Safety of Topical Glycopyrronium Tosylate (GT) in Patients with Axillary Hyperhidrosis

Page s95

Patient-Reported Outcomes from Two Randomized, Double-Blind, Vehicle-Controlled Phase 3 Trials in Axillary Hyperhidrosis (ATMOS-1 & ATMOS-2)

Page s96

Why Publish this Special Issue? A New Paradigm in the Use of Technology to Aid in the Widespread Dissemination of Dermatologic Knowledge

Page s1

SKIN Fall Clinical Dermatology Conference® Poster Supplement Copyright Statement

Achieving an Endpoint of Completely Clear of Inflammatory Lesions and Erythema After Treatment of Rosacea Provides Multiple Positive Patient Outcomes: A Pooled Analysis

Page s58

The Anti-Inflammatory Properties of Ivermectin and Brimonidine in the Treatment of Papulopustular Rosacea

Page s59

Concurrent Administration of Ivermectin 1% Cream with Brimonidine 0.33% Gel Improves Efficacy and Tolerability in the Treatment of Moderate-to-Severe Rosacea

Page s60

Consistent Efficacy and Safety in Four Double-Blind, Vehicle-Controlled Studies of Ivermectin 1% Cream in the Treatment of Moderate-to-Severe Papulopustular Rosacea

Page s61

Evaluation of the Safety and Efficacy of Ultherapy for the Treatment of Signs and Symptoms of Erythematotelangiectatic Rosacea

Page s62

Topical Minocycline Foam (FMX-103) for the Treatment of Moderate-to-Severe Rosacea: Results of a Phase 2, Randomized, Double-Blind, Multicenter Clinical Study

Page s63

An Adhesive Patch Biopsy Based Gene Expression Test to Non-invasively Differentiate Basal Cell and Squamous Cell Carcinomas from Actinic Keratoses and Other Skin Lesions of Similar Appearance

Page s111

BF-200 ALA for the Photodynamic Treatment of Non-Aggressive Basal Cell Carcinoma: Results of a Phase III Comparator Trial

Page s112

Characterization of BF-200 ALA: A Nanoemulsion-Based Drug Delivery System for ALA-PDT

Page s113

Comparison of Electronic Brachytherapy and Mohs Micrographic Surgery for the Treatment of Early-Stage Non-Melanoma Skin Cancer: A Matched Pair Cohort Study

Page s114

Daylight Photodynamic Therapy of Actinic Keratosis with BF-200 ALA compared to MAL

Page s115

Photodynamic Therapy for Actinic Keratosis and Field Cancerization Using BF-200 ALA: Results of Pivotal Phase III Trials and Follow-Up

Page s117

Prevention of Actinic Keratosis by a Very High UVB/UVA Daily Photoprotectant

Page s118

Safety and Efficacy of A-101 Hydrogen Peroxide Topical Solution in Adults with Seborrheic Keratosis: Results from the Phase 3, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study

Page s119

Sonidegib Efficacy and Safety in Patients with Locally Advanced Basal Cell Carcinoma Based on Tumor Aaggressiveness

Page s120

Triple Hedgehog Pathway Inhibition for Treatment of Basal Cell Carcinoma

Page s121

Low Rate of Keloid Recurrences Following Treatment of Keloidectomy Sites with a Biological Effective Dose 30 of Superficial Radiation

Page s122

Observer-Blinded, Randomized Study to Determine the Safety and Efficacy of a Silicone Gel versus a Gel Containing Onion Extract for the Appearance and Symptoms of Surgical Scars

Page s123

Pilot Study Assessing the Efficacy of a Novel Topical Adhesive for Dermatologic Excisional Wound Closure

Page s124

Design and rational of the OPTIMA Study: Retreatment or Step-Up Therapy with Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria (CIU/CSU)

Page s125

Efficacy and Safety of Omalizumab in Japanese and Korean Patients with Chronic Idopathic/Spontaneous Urticaria (CIU/CSU: Results from the Phase 3 POLARIS Study

Page s126

Omalizumab Retreatment of Patients swith Chronic Idopathic Urticaria/Spontaneous Urticaria (CIU/CSU) Following Return of Symptoms: Primary Results of the OPTIMA Study

Page s127

Abametapir Lotion, 0.74% Demonstrates High Elimination Rates of Head Lice with a Single Application in Phase 3 Trials

Page s131

Abametapir Lotion, 0.74%, a Novel Therapy for the Treatment of Head Lice, Pooled Safety Results from 11 Trials, in Children as Young as 6 Months

Page s132

A Randomized Double-Blind, Vehicle-Controlled Study of the Ovicidal Efficacy of a New Head Lice Therapy, Abametapir Lotion, 0.74%, Administered for the Treatment of Head Lice Infestation

Page s133